Repron Therapeutics Srl, a start-up biotech company with epigenetic silencing technology, was launched on 14 April following the completion of a €2 million seed financing round led by Claris Ventures of Turin, Italy. Based in Milan, Repron was founded by Vania Broccoli and Alessandro Sessa, both affiliated with San Raffaele Hospital, the largest private hospital group in Italy. The seed investment is expected to accelerate the development of the epigenetic platform which has been designed to silence oncogene networks in order to repress tumour recurrence in several cancer indications.
